Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Aroa Biosurgery Ltd ( (AU:ARX) ) has issued an announcement.
Aroa Biosurgery Ltd announced a change in the director’s interest, specifically involving Phillip McCaw. The change entails the lapse of 81,925 options due to expiry, impacting McCaw’s indirect holdings through various trusts. This adjustment reflects routine portfolio management and does not indicate any immediate strategic shifts for the company.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
More about Aroa Biosurgery Ltd
Aroa Biosurgery Ltd operates in the biosurgery industry, focusing on developing and manufacturing regenerative tissue products. The company is known for its innovative medical solutions that aid in tissue repair and healing, primarily targeting the healthcare and medical sectors.
Average Trading Volume: 233,663
Technical Sentiment Signal: Buy
Current Market Cap: A$203.6M
Find detailed analytics on ARX stock on TipRanks’ Stock Analysis page.